RELIANCE

Reliance Infrastructure Limited
Registered Office: Reliance Centre, Ground Floor, 19 Walchand Hirachand Marg, Ballard Estate, Mumbai 400 001
website: www.rinfra.com, Email : rinfra.investor@relianceada.com
CIN: L75100MH1929PLC001530
Tel: 91 22 43031000, Fax 91 22 43034662

A. Extract of the Consolidated Financial Results for the Quarter Ended December 31, 2021 (₹ crore)

Sr. No.	Particulars	Quarter ended December 31, 2021 Unaudited	Quarter ended December 31, 2020 Unaudited	Year ended March 31, 2021 Audited
1	Total Income from Operations	**4,846.78**	4,983.91	19,145.81
2	Net Profit / (loss) before exceptional items and tax	**97.58**	212.12	(437.77)
3	Net Profit / (Loss) before tax (after exceptional items)	**97.58**	307.60	(311.43)
4	Net Profit/ (Loss) for the period after tax (after exceptional items)	**(106.91)**	80.08	(532.30)
5	Total Comprehensive Income for the period	**91.34**	431.55	(131.71)
6	Paid-up Equity Share Capital			263.03
7	Earnings Per Share (Face value of ₹ 10 each)			
	(a) Basic (₹)	**(4.07)**	3.04	(20.24)
	(b) Diluted (₹)	**(4.07)**	3.04	(20.24)
	(Not annualised for quarter)			

B. Extract of the Standalone Financial Results for the Quarter Ended December 31, 2021 (₹ crore)

Sr. No.	Particulars	Quarter ended December 31, 2021 Unaudited	Quarter ended December 31, 2020 Unaudited	Year ended March 31, 2021 Audited
1	Total Income from Operations	**320.21**	468.50	1,689.15
2	Net Profit / (loss) before exceptional items and tax	**(192.49)**	(194.06)	(465.08)
3	Net Profit / (Loss) before tax (after exceptional items)	**(192.49)**	37.91	(111.52)
4	Net Profit/ (Loss) for the period after tax (after exceptional items)	**(193.27)**	60.01	(19.08)
5	Total Comprehensive Income for the period	**(193.27)**	60.01	(18.87)
6	Paid up Equity Share Capital			263.03
7	Reserves (excluding Revaluation Reserve)			10,112.55
8	Security Premium Account			8,825.09
9	Net worth			9,724.67
10	Outstanding Debt			3,808.09
11	Debt Equity Ratio	**0.38**	0.55	0.37
12	Earnings Per Share (Face value of ₹ 10 each)			
	(a) Basic (₹)	**(7.35)**	2.28	(0.73)
	(b) Diluted (₹)	**(7.35)**	2.28	(0.73)
	(Not annualised for quarter)			
13	Capital Redemption Reserve	**130.03**	130.03	130.03
14	Debenture Redemption Reserve	**212.98**	212.98	212.98
15	Debt Service Coverage Ratio	**(0.01)**	0.03	0.30
16	Interest Service Coverage Ratio	**(0.29)**	0.95	2.05

C. The consolidated financial results of the Group have been prepared in accordance with the Companies (Indian Accounting Standards) Rules, 2015 (Ind AS) prescribed under section 133 of the Companies Act, 2013.

D. The above is an extract of the detailed format of the financial results for the quarter ended December 31, 2021 drawn up both on a Standalone and Consolidated basis, filed with Stock Exchanges on February 12, 2022 under Regulation 33 and Regulation 52 read with regulation 63(2) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of the Financial Results (Standalone and Consolidated) for the quarter ended December 31, 2021 are available on the Company's website, www.rinfra.com and on the website of the Stock Exchanges, www.bseindia.com and www.nseindia.com.

Place: Mumbai
Date: February 12, 2022

HINDCON CHEMICALS LIMITED
CIN :- L24117WB1998PLC087800
Registered Office :- 62B, Braunfeld Row, 1st Floor, Kolkata – 700 027
Email id :- contactus@hindcon.com , Website :- www.hindcon.com

EXTRACT OF THE UNAUDITED STANDALONE AND CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTHS ENDED 31ST DECEMBER, 2021

(Rs. in Lakhs)

Sl No.	Particulars	Standalone Results: Quarter ended on 31/12/2021 (Unaudited)	Standalone: Year to date as on 31/12/2021 (Unaudited)	Standalone: Corresponding 3 months ended in the Previous Year 31/12/2020 (Unaudited)	Consolidated Results: Quarter ended on 31/12/2021 (Unaudited)	Consolidated: Year to date as on 31/12/2021 (Unaudited)	Consolidated: Corresponding 3 months ended in the Previous Year 31/12/2020 (Unaudited)
1	Total income from operations (net)	1,692.04	4,358.36	1,296.52	1,698.51	4,627.69	1,299.41
2	Net Profit for the period (Before Tax and Exceptional items)	157.69	471.07	163.17	163.42	452.28	165.17
3	Net Profit/(Losses) for the period before tax (After Exceptional items)	157.69	471.07	163.17	163.42	452.28	165.17
4	Total Comprehensive Income for the period (Comprising Profit for the period after tax and Other Comprehensive Income after Tax)	134.69	460.05	181.46	127.88	432.17	192.58
5	Paid up Equity Share Capital (Face Value ₹10/- each)	1,023.81	1,023.81	1,023.81	767.20	767.20	767.20
6	Reserves (excluding Revaluation Reserve) as shown in the Audited Balance Sheet of the Previous Year	-	-	-	-	-	-
7	Basic & Diluted Earnings Per Share (Face Value ₹10/- each) (not Annualised)	1.10	3.48	1.19	1.39	3.98	1.61

Notes:

1 The above is an extract of the detailed format of Quarterly Unaudited Financial Results filed with the National Stock Exchange under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of the Quarterly Financial Results is available on the company's Website - (https://www.hindcon.com) and National Stock Exchange website - (www.nseindia.com).

2 The Company has prepared the Consolidated Financial Statement on annual basis and the Consolidated financial figures include subsidary of the Company viz Hindcon Solutions Pvt Ltd.

3 The Statutory Auditors have provided un-modified report on Unaudited Financial Results (Standalone & Consolidate) for quarter & nine months ended on 31.12.2021.

4 The previous period figures have been regrouped/rearranged wherever necessary, to confirm to the current period figures.

For and on behalf of the Board
Hindcon Chemicals Limited
Sd/-
(Sanjay Goenka)
Chairman & Managing Director
DIN - 00848190

Place : Kolkata
Date : February 12, 2022.

UNITED CREDIT LIMITED
CIN : L65993WB1970PLC027781
Regd. Office : 27B, Camac Street (8th Floor), Kolkata - 700016
Ph.No. (033) 2287-9359/9360, Fax No. (033) 2287-2047
Email: unitedcreditltd@gmail.com, Website: www.unitedcreditltd.com

EXTRACT OF UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTHS ENDED DECEMBER 31, 2021

(₹ in Lakhs)

Sl. No.	Particulars	Quarter ended 31/12/2021 Unaudited	Nine Months ended 31/12/2021 Unaudited	Quarter ended 31/12/2020 Unaudited
1	Total income from operations	55.93	176.12	66.41
2	Net Profit/(Loss) for the period (before Tax, Exceptional and/or Extraordinary items)	16.99	60.41	27.03
3	Net Profit /(Loss) for the period before tax (after Exceptional and/or Extraordinary items)	16.99	60.41	27.03
4	Net Profit/(Loss) for the period after tax (after Exceptional and/or Extraordinary items)	19.58	49.08	19.99
5	Total Comprehensive Income for the period [comprising Profit/(Loss) for the period (after tax) and other comprehensive Income (after tax)]	19.58	49.08	19.99
6	Equity Share Capital	549.30	549.30	549.30
7	Reserves (excluding Revaluation Reserve) as shown in the Audited Balance Sheet of the previous year ended 31st March			
8	Earnings Per Share (of Rs.10/- each) (for continuing and discontinued operations) -			
	(i) Basic	0.37	0.92	0.38
	(ii) Diluted	0.37	0.92	0.38

NOTE:

I) The above is an extract of the detailed format of unaudited Financial Results for the Quarter and Nine Months ended 31.12.2021 filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

ii) The full format of the Quarterly and Nine Months Financial Results are available on the websites of the Stock Exchanges at www.bseindia.com, www.cse-india.com and also on the Company's website at www.unitedcreditltd.com.

By ORDER OF THE BOARD
(A. K. DABRIWALA)
Chairman & Managing Director
DIN : 00024498

Place : Kolkata
Dated : 11th February , 2022

---

glenmark

GLENMARK PHARMACEUTICALS LIMITED
Registered Office: B/2, Mahalaxmi Chambers, 22, Bhulabhai Desai Road, Mahalaxmi, Mumbai - 400 026.
Corporate Office: Glenmark House, B. D. Sawant Marg, Chakala, Off Western Express Highway, Andheri (East), Mumbai - 400 099.
Tel No.: +91-22-4018 9999 **Fax No.:** +91-22-4018 9986
Email: complianceofficer@glenmarkpharma.com **Website:** www.glenmarkpharma.com
CIN: L24299MH1977PLC019982

Statement of unaudited financial results for the quarter and nine months ended 31 December, 2021

(All amounts in million of Indian Rupees, unless otherwise stated)

	Particulars	Standalone: Quarter ended 31/12/2021 (Unaudited)	Standalone: Quarter ended 30/09/2021 (Unaudited)	Standalone: Quarter ended 31/12/2020 (Unaudited)	Standalone: Nine months ended 31/12/2021 (Unaudited)	Standalone: Nine months ended 31/12/2020 (Unaudited)	Standalone: Year ended 31/03/2021 (Audited)	Consolidated: Quarter ended 31/12/2021 (Unaudited)	Consolidated: Quarter ended 30/09/2021 (Unaudited)	Consolidated: Quarter ended 31/12/2020 (Unaudited)	Consolidated: Nine months ended 31/12/2021 (Unaudited)	Consolidated: Nine months ended 31/12/2020 (Unaudited)	Consolidated: Year ended 31/03/2021 (Audited)
I	Revenue from operations												
	(a) Net sales	20,073.59	21,598.94	19,498.23	62,964.93	56,277.60	74,509.11	31,414.72	31,254.26	27,587.36	92,130.46	79,761.37	108,060.26
	(b) Other operating income	256.95	209.72	226.55	595.44	898.05	1,170.22	319.42	220.21	280.27	727.10	1,078.92	1,379.03
	Total revenue from operations	20,330.54	21,808.66	19,724.78	63,560.37	57,175.65	75,679.33	31,734.14	31,474.47	27,867.63	92,857.56	80,840.29	109,439.29
II	Other income	2,167.43	806.96	811.27	4,356.47	2,793.80	3,962.37	138.95	(130.72)	150.90	594.72	417.23	502.16
III	Total income (I + II)	22,497.97	22,615.62	20,536.05	67,916.84	59,969.45	79,641.70	31,873.09	31,343.75	28,018.53	93,452.28	81,257.52	109,941.45
IV	Expenses												
	(a) Cost of materials consumed	6,426.96	8,144.13	6,903.32	23,030.61	20,324.09	26,782.60	7,202.05	8,513.99	7,828.98	24,888.23	23,519.30	31,378.05
	(b) Purchases of stock-in-trade	1,255.58	1,180.91	897.98	3,838.10	2,319.22	3,159.55	2,744.00	2,862.73	2,532.35	8,792.64	5,726.96	7,502.69
	(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	49.98	(44.53)	(197.44)	46.72	(313.05)	52.40	772.89	58.81	(1,247.66)	(136.70)	(1,641.78)	(1,892.54)
	(d) Employee benefits expense	2,943.66	3,491.84	2,806.54	9,076.72	8,554.66	11,073.96	5,859.91	6,873.29	5,966.43	18,697.39	18,065.03	23,437.07
	(e) Finance costs	497.72	532.45	830.41	1,620.31	2,033.91	2,658.98	666.95	689.46	954.07	2,112.44	2,697.79	3,531.13
	(f) Depreciation, amortisation and impairment expense	407.98	396.83	412.12	1,179.22	1,138.15	1,508.15	1,189.30	1,231.90	1,151.98	3,551.92	3,324.85	4,435.54
	(g) Other expenses	4,549.54	4,441.25	4,012.02	12,301.86	10,947.38	15,707.41	8,223.77	7,263.96	7,486.81	22,047.01	19,561.25	28,170.21
	Total expenses (IV)	16,131.42	18,142.88	15,664.95	51,093.54	45,004.36	60,943.05	26,658.87	27,494.14	24,672.96	79,952.93	71,253.40	96,562.15
V	Profit/(loss) before exceptional items and tax (III - IV)	6,366.55	4,472.74	4,871.10	16,823.30	14,965.09	18,698.65	5,214.22	3,849.61	3,345.57	13,499.35	10,004.12	13,379.30
VI	Exceptional items loss/(gain) (Refer note 5)	-	(4,303.33)	(459.02)	(4,303.33)	(738.92)	(738.92)	1,783.80	-	(134.15)	1,783.80	(445.45)	(445.45)
VII	Profit/(loss) before tax (V - VI)	6,366.55	8,776.07	5,330.12	21,126.63	15,704.01	19,437.57	3,430.42	3,849.61	3,479.72	11,715.55	10,449.57	13,824.75
VIII	Tax expense :												
	Current tax	1,406.48	1,250.76	932.03	3,708.13	2,746.89	3,436.18	1,631.30	1,232.01	1,212.43	4,309.30	3,902.49	4,981.40
	Deferred tax	(525.12)	(17.27)	(25.16)	(503.44)	(119.64)	(493.08)	(598.39)	(130.45)	(214.50)	(804.58)	(815.06)	(857.53)
IX	Profit/(loss) for the period (VII - VIII)	5,485.19	7,542.58	4,423.25	17,921.94	13,076.76	16,494.47	2,397.51	2,748.05	2,481.79	8,210.83	7,362.14	9,700.88
	Profit/(loss) for the period attributable to:												
	- Non-controlling interests	-	-	-	-	-	-	178.49	171.45	0.83	349.57	1.73	0.50
	- Owners of the Company	5,485.19	7,542.58	4,423.25	17,921.94	13,076.76	16,494.47	2,219.02	2,576.60	2,480.96	7,861.26	7,360.41	9,700.38
X	Other comprehensive income												
	A (i) Items that will not be reclassified to profit or loss	11.59	(21.48)	5.11	15.76	16.06	32.33	17.28	(67.36)	(0.51)	(24.49)	(138.03)	51.79
	(ii) Income tax relating to items that will not be reclassified to profit or loss	(4.77)	8.23	(1.79)	(5.50)	(5.62)	(7.49)	(4.99)	15.16	(0.58)	1.65	14.76	(7.47)
	B (i) Items that will be reclassified to profit or loss	-	-	-	-	-	-	82.22	(532.39)	1,125.91	525.78	1,094.38	719.81
	(ii) Income tax relating to items that will be reclassified to profit or loss	-	-	-	-	-	-	(10.88)	5.44	(77.86)	(72.76)	121.04	102.68
XI	Total comprehensive income	5,492.01	7,529.33	4,426.57	17,932.20	13,087.20	16,519.31	2,481.14	2,168.90	3,528.75	8,641.01	8,454.29	10,567.69
XII	Total comprehensive income attributable to:												
	- Non-controlling interests	-	-	-	-	-	-	178.52	171.58	0.83	349.73	1.73	0.50
	- Owners of the Company	5,492.01	7,529.33	4,426.57	17,932.20	13,087.20	16,519.31	2,302.62	1,997.32	3,527.92	8,291.28	8,452.56	10,567.19
XIII	Paid up Equity Share Capital, Equity Shares of Rs. 1/- each	282.17	282.17	282.17	282.17	282.17	282.17	282.17	282.17	282.17	282.17	282.17	282.17
XIV	Other equity						147,812.89						70,364.10
XV	Earning per share (EPS)												
	(of Re 1/- each) (not annualised)*												
	Basic EPS (in Rupees)	19.44	26.73	15.68	63.52	46.34	58.46	7.86	9.13	8.80	27.86	26.09	34.38
	Diluted EPS (in Rupees)	19.44	26.73	15.68	63.52	46.34	58.46	7.86	9.13	8.80	27.86	26.09	34.38

*** except for the year ended 31 March**

Notes:

1 The Financial results have been prepared in accordance with Indian Accounting Standards ('Ind AS') prescribed under Section 133 of the Companies Act, 2013 read with relevant rules thereunder and in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended).

2 The above results were reviewed by the Audit Committee at its meeting held on 10 February 2022 and approved by the Board of Directors at their meetings held on 11 February, 2022.

3 The results for the quarter and Nine months ended 31 December, 2021 presented were subjected to a "Limited Review" by statutory auditors of the Company who have issued an unmodified report on the said results.

4 The date of implementation of the Code on Wages 2019 and the Code on Social Security, 2020 is yet to be notified by the Government. The Company will assess the impact of these Codes and give effect in the financial results when the Rules/Schemes thereunder are notified.

5 Exceptional item:
Exceptional item of Rs. 1,783.80 in consolidated result for the quarter and nine months ended 31 December 2021 comprises of impairment of certain intangible assets. On 3 August 2021, Glenmark Life Sciences Limited (GLS) completed allottment of shares as part of its Initial Public Offering (IPO) and Offer for Sale (OFS). The company offered 6.3 million equity shares of Rs 2 each through OFS and resulted in a gain of Rs 4,303.33 (net of related expenses and cost of equity shares) and recorded as an exceptional item in the standalone financial results. Pursuant to requirements of Ind AS 110 para 23 and B96 such gain and tax thereon is directly recognised in equity in consolidated financial statements. Post the sale and IPO, the Company's holding in equity shares of GLS has reduced from 100% to 82.84 %.
Exceptional items in the standalone financial results for the quarter and nine months ended 31 December, 2020 of Rs. 459.02 and Rs. 738.92 respectively and in the consolidated financial results for the quarter and nine months ended 31 December, 2020 of Rs. 134.15 and Rs. 445.45 respectively are on account of gain from transfer of intimate hygiene brand Vwash, Momat brands in certain geographies, sale of IP assets and reimbursement of onetime costs.

6 The Chief Operating Decision Maker ("CODM") reviews the financial performance at pharmaceutical business level, comprising of generics and active pharmaceutical ingredient components, which are interlinked and inter-dependent, therefore, the Company has only one reportable segment, i.e., Pharmaceuticals.

7 As at 31 December, 2021, pursuant to Employee Stock Options Scheme 2016, 404,247 options were outstanding, which upon exercise are convertible into equivalent number of equity shares.

8 The list of subsidiaries as of 31 December 2021 is provided in Annexure A.

9 The Group continues to closely monitor the impact of the COVID-19 pandemic on all aspects of its business, including how it has impacted and how it will impact its customers, employees, vendors and business partners. The management has exercised due care, in concluding on significant accounting judgements and estimates, inter-alia, recoverability of receivables, assessment for impairment of goodwill, investments, intangible assets, inventory, based on the information available to date, both internal and external, while preparing the financial results for the quarter and Nine months ended 31 December, 2021.

10 Diluted EPS has been computed considering the effect of conversion of ESOPs.

11 Previous period's figures have been re-grouped/re-classified to render them comparable with the figures of the current period.

Annexure A
List of entities included in the consolidated financial results for quarter and nine moths ended 31 December 2021

1 Glenmark Pharmaceuticals Europe Ltd., U.K. **2** Glenmark Pharmaceuticals (Europe) R&D Ltd., U.K. (liquidated with effect from 4 January 2022) **3** Glenmark Pharmaceuticals S.R.O. **4** Glenmark Pharmaceuticals SK, S.R.O. **5** Ichnos Sciences SA (Formerly known as Glenmark Pharmaceuticals S. A.) **6** Glenmark Holding S.A. **7** Glenmark Pharmaceuticals S.R.L (liquidated with effect from 30 July 2020) **8** Glenmark Pharmaceuticals SP z.o.o. **9** Glenmark Pharmaceuticals Inc. **10** Glenmark Therapeutics Inc. **11** Glenmark Farmaceutica Ltda **12** Glenmark Generics S.A **13** Glenmark Pharmaceuticals Mexico, S.A. DE C.V. **14** Glenmark Pharmaceuticals Peru SAC **15** Glenmark Pharmaceuticals Colombia SAS, Colombia **16** Glenmark Uruguay S.A. **17** Glenmark Pharmaceuticals Venezuela, C.A **18** Glenmark Dominicana SRL **19** Glenmark Pharmaceuticals Egypt S.A.E. **20** Glenmark Pharmaceuticals FZE **21** Glenmark Impex L.L.C **22** Glenmark Philippines Inc. **23** Glenmark Pharmaceuticals (Nigeria) Ltd **24** Glenmark Pharmaceuticals Malaysia Sdn Bhd **25** Glenmark Pharmaceuticals (Australia) Pty Ltd **26** Glenmark South Africa (pty) Ltd **27** Glenmark Pharmaceuticals South Africa (pty) Ltd **28** Glenmark Pharmaceuticals (Thailand) Co. Ltd **29** Glenmark Pharmaceuticals B.V. **30** Glenmark Arzneimittel Gmbh **31** Glenmark Pharmaceuticals Canada Inc. **32** Glenmark Pharmaceuticals Kenya Ltd **33** Viso Farmaceutica S.L., Spain **34** Glenmark Specialty SA **35** Glenmark Pharmaceuticals Distribution s.r.o. **36** Glenmark Pharmaceuticals Nordic AB **37** Glenmark Ukraine LLC **38** Glenmark Pharmaceuticals Ecuador S.A. **39** Glenmark Pharmaceuticals Singapore Pte. Ltd. **40** Ichnos Sciences Biotherapeutics SA (Formerly known as Glenmark Biotherapeutics SA) **41** Ichnos Sciences Inc., USA (w.e.f. 31 May, 2019) **42** Glenmark Life Sciences Limited **43** Glenmark Distribuidora De Medicamentos E Produtos Cosmeticos Ltda. (up to 23 December 2020)

For and on behalf of the Board of Directors

S/d
V.S. Mani
Executive Director & Global Chief Financial Officer

Mumbai, 11 February, 2022

financialexp.epapr.in

मुंब्रा खाडीतील खारफुटीवरील अतिक्रमण हटविले

लोकसत्ता प्रतिनिधी

ठाणे : मुंब्रा येथील देसाई खाडीमधील राखीव वन क्षेत्रात खारफुटी नष्ट करून रस्ता बांधण्यात आल्याचा गंभीर प्रकार उघडकीस आला होता. अखेर शुक्रवारी कांदळवन कक्ष, पोलीस आणि महसूल विभागाने संयुक्त कारवाई करत दीड हेक्टर भागातील अतिक्रमण हटवून बेकायदा रस्ता बंद केला.

वाळू माफियांनी वाळूच्या गाड्यांच्या वाहतूकीसाठी हा रस्ता तयार केला होता. तसेच खाडीतून अवैधरित्या काढलेली वाळू साठविण्यासाठी येथे दोन मोठे हौदही तयार केले होते. हे हौदही तोडण्यात आले.

मुंब्रा येथील चुहा पूल ते दिवा या भागात खाडीमध्ये खारफुटींवर भराव टाकून रस्ता तयार करण्यात आल्याचा प्रकार उघडकीस आला होता. त्याबाबतचे वृत्त 'लोकसत्ता'मध्ये 'टाळेबंदीत खारफुटींची बेसुमार कत्तल' या मथळ्याखाली प्रसिद्ध झाले होते. त्याची दखल घेत कांदळवन कक्षाने घटनास्थळी जाऊन पाहणी केली असता या ठिकाणी रस्ता बांधण्यात आल्याचे स्पष्ट झाले. तसेच रमेश पाटील यानेही खाडीत भराव टाकून विवाह समारंभासाठी मोठे मंडप उभारल्याचे आढळले होते. त्याच्या चौकशीत गणेश पाटील याचेही नाव पुढे आले. त्यानुसार या दोघांविरोधात कांदळवन कक्षाने गुन्हे दाखल केले होते.

> **ठाणे आणि भिवंडी भागातील खारफुटी नष्ट करून अतिक्रमण करणाऱ्यांविरोधात गुन्हे दाखल करण्यात येणार आहेत.**
> - चेतना शिंदे,
> वनपरिक्षेत्र अधिकारी, कांदळवन कक्ष

दरम्यान, इतक्या मोठ्याप्रमाणात खारफुटी नष्ट करण्यात आल्याने तेथील अतिक्रमण हटविण्याचे आव्हान अधिकाऱ्यांसमोर होते. अखेर शुक्रवारी कांदळवन कक्ष, महसूल आणि पोलीस यांनी संयुक्त कारवाई केली. येथील दीड हेक्टर परिसरातील अतिक्रमण हटवून तेथील बेकायदा रस्ता बंद करण्यात आला. ही कारवाई करताना वाळू माफियांनी खाडीमधून अवैधरित्या काढलेली वाळू साठविण्यासाठी दोन हौदही बांधल्याचे निदर्शनास आले. ते हौदही तोडण्यात आले. कांदळवन कक्षाने तेथे आता रस्त्याच्या ठिकाणी चर खोदण्यास सुरूवात केली आहे. याठिकाणी खारफुटींच्या सहयोगी वनस्पतींची लागवड करण्याचा विचार सुरू असल्याचे एका अधिकाऱ्याने सांगितले.

SBI STATE BANK OF INDIA
REGIONAL BUSINESS OFFICE, NAVI MUMBAI (5141)
G 101 TO G 106, Tower - 3, 1st Floor, Belapur Railway Station Complex, CBD, Belapur, Navi Mumbai - 400614.

GOLD AUCTION NOTICE

The borrowers in specific and the public, in general are hereby notified that public auction of Gold ornaments pledge is proposed to be conducted at the following branches on below mention date. The auction of Gold ornaments of defaulted customer who have failed to make payment of their loan amounts despite being notified by registered letters. The change in venue or date (if any) will be displayed at the auction centre. Un-auctioned Gold items shall be auctioned on subsequent working days after displaying the details at auction centre. **The auction will be conducted on 18.02.2022 from 10 am onwards at the following branches of State Bank of India.**

1) Vasundhara Heights Juinagar Branch (21464): Shop No. 4-7, Plot No.5, Vasundhara Heights Bldg, Sec-11, Opp. Juinagar Rly Station, Sanpada, Navi Mumbai - 400705. Mobile - 81498 55898

NOTE : BANK HAS RESERVE THE RIGHTS TO CANCEL THE AUCTION AT ALL LOCATION WITHOUT PRIOR INTIMATION.

Authorised Officer
For State Bank of India

पश्चिम रेल्वे चालविणार सुरत - मडगाव दरम्यान विशेष गाडी

गाडी क्र.	मूळ स्थानक आणि गन्तव्य स्थान	सेवेची तारीख	प्रयाण	आगमन
०९१९३	सुरत - मडगाव	१५.०२.२०२२	सायं. ०७.५० वाजता (मंगळवारी)	दुपारी १२.३० वाजता (दुसऱ्या दिवशी)
०९१९४	मडगाव - सुरत	१६.०२.२०२२	दुपारी ०१.४० वाजता (बुधवारी)	सकाळी ०८.३५ वाजता (दुसऱ्या दिवशी)

विरामस्थाने : वलसाड, वापी, पालघर, वसई रोड, पनवेल, रोहा, माणगाव, खेड, चिपळूण, संगमेश्वर रोड, रत्नागिरी, राजापूर रोड, वैभववाडी रोड, कणकवली, सिंधुदुर्ग, कुडाळ, सावंतवाडी रोड, थिविम आणि करमाली स्थानके दोन्ही दिशांनी प्रवासादरम्यान.

रचना : एसी चेअर कार आणि सेकण्ड क्लास सीटिंग कोचेस.

वेळापत्रक, विरामस्थाने आणि रचना संदर्भातील सविस्तर माहितीकरिता प्रवाशांनी कृपया **www.enquiry.indianrail.gov.in** मध्ये भेट द्यावी.

फक्त कन्फर्म्ड तिकिटे असलेल्या प्रवाशांनाच या विशेष गाडीत चढता येईल.

पश्चिम रेल्वेकडून प्रवाशांना विनंती करण्यात येते की, गाडीत चढताना, प्रवास करताना आणि गन्तव्य स्थानी कोविड-१९ संबंधित एसओपींचे सर्व नियमांचे पालन करावे.

गाडी क्र. ०९१९३ चे बुकिंग १३ फेब्रुवारी २०२२ पासून पीआरएस काऊन्टर्सवर आणि आयआरसीटीसी वेबसाइटवर सुरू.
वरील गाडी विशेष प्रवासभाड्यावर पूर्णतः आरक्षित विशेष गाडी म्हणून चालविण्यात येईल.

पश्चिम रेल्वे
www.wr.indianrailways.gov.in
आम्हाला लाइक करा : facebook.com/WesternRly
आम्हाला फॉलो करा : twitter.com/WesternRly
Azadi Ka Amrit Mahotsav

सर्व आरक्षित तिकिटांवर प्रवास करताना कृपया मूळ आयडी प्रूफ स्वतःजवळ ठेवा.

दि महाराष्ट्र स्टेट को-ऑपरेटिव्ह बँक लि., मुंबई
(दि विदर्भ को-ऑपरेटिव्ह बँक लि., सम्मिलित)
शेड्युल्ड बँक
मुख्य कचेरी :- सर विठ्ठलदास ठाकरसी स्मृती भवन,९, महाराष्ट्र चेंबर ऑफ कॉमर्स लेन, फोर्ट, मुंबई - ४०० ००१.

विशेष सर्वसाधारण सभेची सूचना

बँकेच्या सर्व सन्माननीय सभासदांना सूचना देण्यात येते की, बँकेची विशेष सर्वसाधारण सभा, सोमवार, दिनांक २८ फेब्रुवारी, २०२२ रोजी दुपारी ठीक १२.०० वाजता, सहकार सभागृह, ४ था मजला, मुख्य कचेरी येथे (भारतीय प्रमाणवेळेनुसार) व्हीसीद्वारे (Video Conference) ऑनलाईन पध्दतीने बँकेचे मा.प्रशासक यांच्या अध्यक्षतेखाली खालील कामकाजाकरीता भरेल.

विषय

१. मा. प्रशासक महोदय यांनी शिफारस केलेल्या पुढील उपविधी दुरुस्तीस मान्यता देणे.

Subject	Bye-laws no.	Original Bye-laws	Amendment to be made
Membership of category "B"	14 (a)	New Addition	New sub-clause (vi) is to be added as:- vi) is a borrower Primary Agricultural Co-operative Society (PACS) who is a member of respective District Central Co-operative Bank (DCCB) and to whom the said DCC Bank has issued No Objection Certificate to become a 'B' class member of the Bank.

२. मा. प्रशासक महोदय यांच्या अनुमतीने सभेपुढे आयत्यावेळी येणाऱ्या विषयांवर विचार करणे.

मा. प्रशासक यांच्या हुकूमावरुन
सही/-
(डॉ. अजित आर. देशमुख)
व्यवस्थापकीय संचालक

स्थळः मुंबई
दिनांक : १३ फेब्रुवारी, २०२२

विशेष सूचना

१. सदर सभा ऑनलाईन पध्दतीने आयोजित करण्यात येणार असल्याने सभेत सहभागी होण्यासाठी सभासदांना खालीलप्रमाणे कार्यवाही करावी लागेल.
   १.१ सभासद इंटरनेट सुविधा उपलब्ध असलेल्या संगणक, लॅपटॉप, स्मार्टफोनव्दारे विशेष सर्वसाधारण सभेमध्ये ऑनलाईन सहभागी होऊ शकतील.
   १.२ सभासदांनी आपल्या संस्थेचे नाव, पत्ता, सभासद क्र., मोबाईल क्र. आणि ई-मेल आयडी इत्यादी माहिती दि. २१ फेब्रुवारी २०२२ पूर्वी mscbkg@mscbank.com या ई-मेलवर तसेच लेखी स्वरुपात, बँकिंग (शेअर्स) विभाग, मुख्य कार्यालय, दि महाराष्ट्र स्टेट को-ऑप. बँक लि., मुंबई, सर विठ्ठलदास ठाकरसी स्मृती भवन, ९, महाराष्ट्र चेंबर ऑफ कॉमर्स लेन, फोर्ट, मुंबई - ४००००१ येथे कळवावी. अधिक माहितीसाठी श्री. राजेंद्र टी. सुर्वे, व्यवस्थापक, बँकिंग विभाग (मोबाईल क्र. ९५८८६५२२४२) व श्री. प्रमोद वाय. गरुड, सहाय्यक व्यवस्थापक, बँकिंग (भाग) विभाग (मोबाईल क्र.९१६९४००२२६) यांचेशी संपर्क साधावा.
   १.३ सभासदांनी वर नमूद आवश्यक माहिती दि.२१ फेब्रुवारी २०२२ पुर्वी बँकेकडे सादर करावी जेणेकरुन सभेच्या दिवशी ऑनलाईन सभेची लिंक, युजर आयडी व पासवर्ड त्यांना उपलब्ध करुन देता येईल आणि ते सभेमध्ये सहभागी होऊ शकतील. सभेत सहभागी होण्यासाठी आवश्यक तपशिलवार कार्यपध्दती बँकेच्या **https://www.mscbank.com** या संकेत स्थळावर दि.२१ फेब्रुवारी २०२२ प्रसिध्द करीत आहोत.
   १.४ सभासद सभेपूर्वी दहा मिनिटे आधी अधिकृत लिंकव्दारे सभेसाठी जॉईन होऊ शकतील.
   १.५ सभेस आवश्यक असलेली गणसंख्या जर दुपारी ठिक १२.०० वाजेपर्यंत पूर्ण झाली नाही तर सदर सभा पुढे ढकलली जाईल व अशी पुढे ढकलेली सभा त्याच दिवशी, ऑडीओ व्हिज्युअल पध्दतीने दुपारी ठिक १२.३० वाजता मूळ विषयपत्रिकेवरील कामकाज पार पाडण्यासाठी आयोजित करण्यात येईल. त्या सभेस गणपूर्तीची वा स्वतंत्र सूचनेची आवश्यकता राहणार नाही.
   १.६ काही अनपेक्षित परिस्थितीत सदर ऑनलाईन सभेचे कामकाज खंडित झाल्यास, तांत्रिक त्रुटींचे निवारण झाल्यानंतर त्याच लिंकवर सभेचे कामकाज पुन्हा पुढे सुरु केले जाईल. कोणत्याही सभासदास तांत्रिक अडचणींमुळे सभेस जॉईन होता आले नाही तर त्यास बँक जबाबदार राहणार नाही.
२. ज्या सहकारी संस्थांनी विशेष सर्वसाधारण सभेस ऑनलाईन पध्दतीने हजर राहण्यासाठी व त्या सभेमध्ये मत देण्यासाठी आपले प्रतिनिधी नियुक्त केले असतील, त्या प्रतिनिधींना सदर अधिकार दिलेल्या ठरावाची प्रमाणित प्रत उशिरात उशिरा बँकेस शुक्रवार दिनांक २५ फेब्रुवारी २०२२ रोजी अथवा तत्पूर्वी पोहोचेल अशा बेताने पाठवावी.
३. सदर सभेची सूचना बँकेच्या **https://www.mscbank.com** या संकेत स्थळावर उपलब्ध आहे.

Glenmark

GLENMARK PHARMACEUTICALS LIMITED
Registered Office: B/2, Mahalaxmi Chambers, 22, Bhulabhai Desai Road, Mahalaxmi, Mumbai - 400 026.
Corporate Office: Glenmark House, B. D. Sawant Marg, Chakala, Off Western Express Highway, Andheri (East), Mumbai - 400 099.
Tel No.: +91-22-4018 9999 **Fax No.:** +91-22-4018 9986
Email: complianceofficer@glenmarkpharma.com **Website:** www.glenmarkpharma.com
CIN: L24299MH1977PLC019982

Statement of unaudited financial results for the quarter and nine months ended 31 December, 2021

(All amounts in million of Indian Rupees, unless otherwise stated)

	Particulars	Standalone						Consolidated					
		Quarter ended 31/12/2021 (Unaudited)	Quarter ended 30/09/2021 (Unaudited)	Quarter ended 31/12/2020 (Unaudited)	Nine months ended 31/12/2021 (Unaudited)	Nine months ended 31/12/2020 (Unaudited)	Year ended 31/03/2021 (Audited)	Quarter ended 31/12/2021 (Unaudited)	Quarter ended 30/09/2021 (Unaudited)	Quarter ended 31/12/2020 (Unaudited)	Nine months ended 31/12/2021 (Unaudited)	Nine months ended 31/12/2020 (Unaudited)	Year ended 31/03/2021 (Audited)
I	Revenue from operations												
	(a) Net sales	20,073.59	21,598.94	19,498.23	62,964.93	56,277.60	74,509.11	31,414.72	31,254.26	27,587.36	92,130.46	79,761.37	108,060.26
	(b) Other operating income	256.95	209.72	226.55	595.44	898.05	1,170.22	319.42	220.21	280.27	727.10	1,078.92	1,379.03
	Total revenue from operations	20,330.54	21,808.66	19,724.78	63,560.37	57,175.65	75,679.33	31,734.14	31,474.47	27,867.63	92,857.56	80,840.29	109,439.29
II	Other income	2,167.43	806.96	811.27	4,356.47	2,793.80	3,962.37	138.95	(130.72)	150.90	594.72	417.23	502.16
III	Total income (I + II)	22,497.97	22,615.62	20,536.05	67,916.84	59,969.45	79,641.70	31,873.09	31,343.75	28,018.53	93,452.28	81,257.52	109,941.45
IV	Expenses												
	(a) Cost of materials consumed	6,426.96	8,144.13	6,903.32	23,030.61	20,324.09	26,782.60	7,202.05	8,513.99	7,828.98	24,888.23	23,519.30	31,378.05
	(b) Purchases of stock-in-trade	1,255.58	1,180.91	897.98	3,838.10	2,319.22	3,159.55	2,744.00	2,862.73	2,532.35	8,792.64	5,726.96	7,502.69
	(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	49.98	(44.53)	(197.44)	46.72	(313.05)	52.40	772.89	58.81	(1,247.66)	(136.70)	(1,641.78)	(1,892.54)
	(d) Employee benefits expense	2,943.66	3,491.84	2,806.54	9,076.72	8,554.66	11,073.96	5,859.91	6,873.29	5,966.43	18,697.39	18,065.03	23,437.07
	(e) Finance costs	497.72	532.45	830.41	1,620.31	2,033.91	2,658.98	666.95	689.46	954.07	2,112.44	2,697.79	3,531.13
	(f) Depreciation, amortisation and impairment expense	407.98	396.83	412.12	1,179.22	1,138.15	1,508.15	1,189.30	1,231.90	1,151.98	3,551.92	3,324.85	4,435.54
	(g) Other expenses	4,549.54	4,441.25	4,012.02	12,301.86	10,947.38	15,707.41	8,223.77	7,263.96	7,486.81	22,047.01	19,561.25	28,170.21
	Total expenses (IV)	16,131.42	18,142.88	15,664.95	51,093.54	45,004.36	60,943.05	26,658.87	27,494.14	24,672.96	79,952.93	71,253.40	96,562.15
V	Profit/(loss) before exceptional items and tax (III - IV)	6,366.55	4,472.74	4,871.10	16,823.30	14,965.09	18,698.65	5,214.22	3,849.61	3,345.57	13,499.35	10,004.12	13,379.30
VI	Exceptional items loss/(gain) (Refer note 5)	-	(4,303.33)	(459.02)	(4,303.33)	(738.92)	(738.92)	1,783.80	-	(134.15)	1,783.80	(445.45)	(445.45)
VII	Profit/(loss) before tax (V - VI)	6,366.55	8,776.07	5,330.12	21,126.63	15,704.01	19,437.57	3,430.42	3,849.61	3,479.72	11,715.55	10,449.57	13,824.75
VIII	Tax expense :												
	Current tax	1,406.48	1,250.76	932.03	3,708.13	2,746.89	3,436.18	1,631.30	1,232.01	1,212.43	4,309.30	3,902.49	4,981.40
	Deferred tax	(525.12)	(17.27)	(25.16)	(503.44)	(119.64)	(493.08)	(598.39)	(130.45)	(214.50)	(804.58)	(815.06)	(857.53)
IX	Profit/(loss) for the period (VII - VIII)	5,485.19	7,542.58	4,423.25	17,921.94	13,076.76	16,494.47	2,397.51	2,748.05	2,481.79	8,210.83	7,362.14	9,700.88
	Profit/(loss) for the period attributable to:												
	- Non-controlling interests	-	-	-	-	-	-	178.49	171.45	0.83	349.57	1.73	0.50
	- Owners of the Company	5,485.19	7,542.58	4,423.25	17,921.94	13,076.76	16,494.47	2,219.02	2,576.60	2,480.96	7,861.26	7,360.41	9,700.38
X	Other comprehensive income												
	A (i) Items that will not be reclassified to profit or loss	11.59	(21.48)	5.11	15.76	16.06	32.33	17.28	(67.36)	(0.51)	(24.49)	(138.03)	51.79
	(ii) Income tax relating to items that will not be reclassified to profit or loss	(4.77)	8.23	(1.79)	(5.50)	(5.62)	(7.49)	(4.99)	15.16	(0.58)	1.65	14.76	(7.47)
	B (i) Items that will be reclassified to profit or loss	-	-	-	-	-	-	82.22	(532.39)	1,125.91	525.78	1,094.38	719.81
	(ii) Income tax relating to items that will be reclassified to profit or loss	-	-	-	-	-	-	(10.88)	5.44	(77.86)	(72.76)	121.04	102.68
XI	Total comprehensive income	5,492.01	7,529.33	4,426.57	17,932.20	13,087.20	16,519.31	2,481.14	2,168.90	3,528.75	8,641.01	8,454.29	10,567.69
XII	Total comprehensive income attributable to:												
	- Non-controlling interests	-	-	-	-	-	-	178.52	171.58	0.83	349.73	1.73	0.50
	- Owners of the Company	5,492.01	7,529.33	4,426.57	17,932.20	13,087.20	16,519.31	2,302.62	1,997.32	3,527.92	8,291.28	8,452.56	10,567.19
XIII	Paid up Equity Share Capital, Equity Shares of Rs. 1/- each	282.17	282.17	282.17	282.17	282.17	282.17	282.17	282.17	282.17	282.17	282.17	282.17
XIV	Other equity						147,812.89						70,364.10
XV	Earning per share (EPS)												
	(of Re 1/- each) (not annualised)*												
	Basic EPS (in Rupees)	19.44	26.73	15.68	63.52	46.34	58.46	7.86	9.13	8.80	27.86	26.09	34.38
	Diluted EPS (in Rupees)	19.44	26.73	15.68	63.52	46.34	58.46	7.86	9.13	8.80	27.86	26.09	34.38

*** except for the year ended 31 March**

Notes:
1 The Financial results have been prepared in accordance with Indian Accounting Standards ('Ind AS') prescribed under Section 133 of the Companies Act, 2013 read with relevant rules thereunder and in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended).
2 The above results were reviewed by the Audit Committee at its meeting held on 10 February 2022 and approved by the Board of Directors at their meetings held on 11 February, 2022.
3 The results for the quarter and Nine months ended 31 December, 2021 presented were subjected to a "Limited Review" by statutory auditors of the Company who have issued an unmodified report on the said results.
4 The date of implementation of the Code on Wages 2019 and the Code on Social Security, 2020 is yet to be notified by the Government. The Company will assess the impact of these Codes and give effect in the financial results when the Rules/Schemes thereunder are notified.
5 Exceptional item:
Exceptional item of Rs. 1,783.80 in consolidated result for the quarter and nine months ended 31 December 2021 comprises of impairment of certain intangible assets. On 3 August 2021, Glenmark Life Sciences Limited (GLS) completed allottment of shares as part of its Initial Public Offering (IPO) and Offer for Sale (OFS). The company offered 6.3 million equity shares of Rs 2 each through OFS and resulted in a gain of Rs 4,303.33 (net of related expenses and cost of equity shares) and recorded as an exceptional item in the standalone financial results. Pursuant to requirements of Ind AS 110 para 23 and B96 such gain and tax thereon is directly recognised in equity in consolidated financial statements. Post the sale and IPO, the Company's holding in equity shares of GLS has reduced from 100% to 82.84 %.
Exceptional items in the standalone financial results for the quarter and nine months ended 31 December, 2020 of Rs. 459.02 and Rs. 738.92 respectively and in the consolidated financial results for the quarter and nine months ended 31 December, 2020 of Rs. 134.15 and Rs. 445.45 respectively are on account of gain from transfer of intimate hygiene brand Vwash, Momat brands in certain geographies, sale of IP assets and reimbursement of onetime costs.
6 The Chief Operating Decision Maker ("CODM") reviews the financial performance at pharmaceutical business level, comprising of generics and active pharmaceutical ingredient components, which are interlinked and inter-dependent, therefore, the Company has only one reportable segment, i.e., Pharmaceuticals.
7 As at 31 December, 2021, pursuant to Employee Stock Options Scheme 2016, 404,247 options were outstanding, which upon exercise are convertible into equivalent number of equity shares.
8 The list of subsidiaries as of 31 December 2021 is provided in Annexure A.
9 The Group continues to closely monitor the impact of the COVID-19 pandemic on all aspects of its business, including how it has impacted and how it will impact its customers, employees, vendors and business partners. The management has exercised due care, in concluding on significant accounting judgements and estimates, inter-alia, recoverability of receivables, assessment for impairment of goodwill, investments, intangible assets, inventory, based on the information available to date, both internal and external, while preparing the financial results for the quarter and Nine months ended 31 December, 2021.
10 Diluted EPS has been computed considering the effect of conversion of ESOPs.
11 Previous period's figures have been re-grouped/re-classified to render them comparable with the figures of the current period.

Annexure A
List of entities included in the consolidated financial results for quarter and nine moths ended 31 December 2021

1 Glenmark Pharmaceuticals Europe Ltd., U.K. **2** Glenmark Pharmaceuticals (Europe) R&D Ltd., U.K. (liquidated with effect from 4 January 2022) **3** Glenmark Pharmaceuticals S.R.O. **4** Glenmark Pharmaceuticals SK, S.R.O. **5** Ichnos Sciences SA (Formerly known as Glenmark Pharmaceuticals S. A.) **6** Glenmark Holding S.A. **7** Glenmark Pharmaceuticals S.R.L (liquidated with effect from 30 July 2020) **8** Glenmark Pharmaceuticals SP z.o.o. **9** Glenmark Pharmaceuticals Inc. **10** Glenmark Therapeutics Inc. **11** Glenmark Farmaceutica Ltda **12** Glenmark Generics S.A **13** Glenmark Pharmaceuticals Mexico, S.A. DE C.V. **14** Glenmark Pharmaceuticals Peru SAC **15** Glenmark Pharmaceuticals Colombia SAS, Colombia **16** Glenmark Uruguay S.A. **17** Glenmark Pharmaceuticals Venezuela, C.A **18** Glenmark Dominicana SRL **19** Glenmark Pharmaceuticals Egypt S.A.E. **20** Glenmark Pharmaceuticals FZE **21** Glenmark Impex L.L.C **22** Glenmark Philippines Inc. **23** Glenmark Pharmaceuticals (Nigeria) Ltd **24** Glenmark Pharmaceuticals Malaysia Sdn Bhd **25** Glenmark Pharmaceuticals (Australia) Pty Ltd **26** Glenmark South Africa (pty) Ltd **27** Glenmark Pharmaceuticals South Africa (pty) Ltd **28** Glenmark Pharmaceuticals (Thailand) Co. Ltd **29** Glenmark Pharmaceuticals B.V. **30** Glenmark Arzneimittel Gmbh **31** Glenmark Pharmaceuticals Canada Inc. **32** Glenmark Pharmaceuticals Kenya Ltd **33** Viso Farmaceutica S.L., Spain **34** Glenmark Specialty SA **35** Glenmark Pharmaceuticals Distribution s.r.o. **36** Glenmark Pharmaceuticals Nordic AB **37** Glenmark Ukraine LLC **38** Glenmark Pharmaceuticals Ecuador S.A. **39** Glenmark Pharmaceuticals Singapore Pte. Ltd. **40** Ichnos Sciences Biotherapeutics SA (Formerly known as Glenmark Biotherapeutics SA) **41** Ichnos Sciences Inc., USA (w.e.f. 31 May, 2019) **42** Glenmark Life Sciences Limited **43** Glenmark Distribuidora De Medicamentos E Produtos Cosmeticos Ltda. (up to 23 December 2020)

For and on behalf of the Board of Directors

S/d
V.S. Mani
Executive Director & Global Chief Financial Officer

Mumbai, 11 February, 2022

epaper.loksatta.com